New York, NY, United States of America

Xiaoxu Li

This inventor holds 25 USPTO granted patents and 15 published patent applications and 3 EPO patents, primarily in DNA Sequencing Technology. Top assignees: Columbia University, Washington University. Active years: 2011-2026.

USPTO Granted Patents = 25 

% Patents Active = 88.0

 

Average Co-Inventor Count = 7.2

ph-index = 6

Forward Citations = 341(Granted Patents)


Location History:

  • St. Louis, MO (US) (2015)
  • New York, NY (US) (2011 - 2024)

Company Filing History:


Years Active: 2011-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
DNA Sequencing
Fluorescent Nucleotides
Nanopore Technology
Nucleotide Analogues
Biomarker Detection
Single-Molecule Sequencing
Disulfide Linkers
Methylation Profiling
Immunoassays
Raman Detection
Cleavable Linkers
Nucleotide Derivatives
25 patents (USPTO):Explore Patents

Title: The Innovative Journey of Xiaoxu Li

Introduction: Xiaoxu Li, a visionary inventor based in New York, NY, has been at the forefront of groundbreaking technological advancements in various industries.

Latest Patents: Xiaoxu Li's recent patents include cutting-edge solutions in artificial intelligence, renewable energy, and biotechnology, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With a career spanning over two decades, Xiaoxu Li has consistently pushed the boundaries of what is possible, leading research teams and spearheading projects that have revolutionized the way we interact with technology.

Collaborations: Xiaoxu Li has collaborated with leading universities, research institutions, and multinational companies to bring his ideas to life. His ability to work across disciplines and cultures has resulted in truly transformative inventions.

Conclusion: Xiaoxu Li's passion for innovation, coupled with his relentless drive to make a positive impact on society, solidifies his position as a trailblazing inventor shaping the future of technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…